Morgans Under the Microscope

Peter Rowland MD of Micro-X explains the significance of the next generation X-ray technology for global health and security markets.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#X-ray #Security #Healthcare

Morgans healthcare analyst Iain Wilkie talks to Dr James Fielding, CEO of new IPO entrant Audeara (ASX:AUA) on what the company does and where its products fit within the audiology space.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Innovation #Healthcare

Rob Wong Chief Executive Officer of Control Bionics, speaks with Scott Power from the Morgans Healthcare team, providing an update on the significant progress the company is making.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Innovation #Healthcare

Morgans analyst Iain Wilkie speaks with Chief Executive Officer and Managing Director of ResApp (ASX:RAP), Tony Keating. Tony provides an update on a number of recent news events.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU

Morgans Senior Analysis, Dr. Derek Jellinek, provides an update on the healthcare universe, including key upcoming catalysts.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/Morgans.AustraliaOn Twitter: twitter.com/MorgansAU#Healthcare #Stocks #ReportingSeason

Morgans Healthcare Analyst Iain Wilkie talks to Pippa Leary, Chief Executive Officer of Swift Media (ASX:SW1) for a high-level overview of the business, catalysts, and its shift into the large aged care sector.

Scott Power from the Morgans Healthcare team speaks with Peter Rowland, CEO from Micro-X (ASX: MX1) where he explains the technology, its application, and upcoming catalysts for 2021.

Healthcare analysts Iain Wilkie and Scott Power wrap up the week with a review and call out on stocks in the IVF sector such as: Virtus Health (VRT) and Monash IVF Group (MVF). Some other stocks mentioned are ImexHS (IME), Swift Media (SW1), and Impedimed (IPD).

Senior Analyst Scott Power from the Morgans Healthcare team speaks with Jon Pilcher, Chief Executive Officer of Neuren Pharmaceuticals (ASX:NEU). Jon explains a number of key catalysts which are expected in 2021.

Morgans analyst Iain Wilkie discusses the healthcare team's initiation of coverage for Antisense Therapeutics (ASX:ANP) and highlights Neuren Pharmaceuticals (ASX:NEU) as a stock with key catalysts ahead.Check out more from Morgans:Visit the Morgans website: www.morgans.com.auCheck out our blog: www.morgans.com.au/BlogOn Facebook: www.facebook.com/MorgansAUOn Instagram: www.instagram.com/morgans.australiaOn Twitter: twitter.com/morgansAU

Scott Power from the Morgans Healthcare team runs through a number of themes for 2021 together with some upcoming catalysts. Stocks mentioned include Pro Medicus (PME), Nanosonics (NAN), EBOS Group (EBO), Micro-X (MX1), Impedimed (IPD) Volpara Health Technologies (VHT), and ResMed (RMD).Check out more from Morgans:Visit the Morgans website: https://www.morgans.com.auCheck out our blog: https://www.morgans.com.au/BlogOn Facebook: https://www.facebook.com/MorgansAUOn Instagram: https://www.instagram.com/morgans.australiaOn Twitter: https://twitter.com/morgansAU#Healthcare #Technology #Morgans

Morgans Analyst Iain Wilkie chats with Claude Solitario, Managing Director of ASX listed mental health technology company Medibio (ASX:MEB). The two chat about an update on a recent partnership as well as a number of upcoming catalysts.

The Morgans Healthcare provides an update on the following companies Promedicus (PME), Nanosonics (NAN), Resmed (RMD), Volpara (VHT), Virtus (VRT), Impedimed (IPD), and Micro-X (MX1)

The Morgans Health team provides an update on the aged care sector and key catalysts achieved (stocks mentioned Micro-X, Impedimed, Virtus, Volpara, Mach 7 and Paradigm)

Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.